Skip to search formSkip to main contentSkip to account menu

Exherin

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ADH-1N-Ac-CHAVC-NH2

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Final clinical and pharmacokinetic (PK) results from a phase 1 study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tumors stratified according to N…
3016 Background: Malignant transformation and invasiveness correlate with upregulation of N-cad, a cell adhesion molecule… 
2006
2006
An enriched phase I, pharmacokinetic and pharmacodynamic study of the N-cadherin (NCAD) cyclic competitive binder exherin (ADH-1) in patients with solid tumors.
3042 Background: N-cad is a cell adhesion molecule expressed by vascular endothelium and tumor cells of invasive tumors. ADH-1, a… 
2005
2005
A phase I study of the novel molecularly targeted vascular targeting agent, Exherin (ADH-1), shows activity in some patients with refractory solid tumors stratified according to N-cadherin expression
3038 Background: Malignant transformation and invasive capacity is highly correlated with upregulation of N-cadherin, a cell… 
2005
2005
Preclinical safety and pharmacokinetic evaluation of Exherin™ (ADH-1) in Beagle dogs
4191 Exherin™ (ADH-1) is a cyclic pentapeptide molecule (N-Ac-CHAVC-NH2) being developed as a cell adhesion inhibitor of N… 
Review
2004
Review
2004
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)